Why the study?
Do secondary prevention therapies improve long-term survival and reduce reinfarctions in patients after myocardial infarction?
Do secondary prevention therapies improve long-term survival and reduce reinfarctions in patients after myocardial infarction?
This review highlights that beta-blockers and platelet-active drugs are effective for secondary prevention after myocardial infarction, while other therapies lacked convincing survival benefits at the time of publication.
Secondary prevention trials after myocardial infarction have been compared and reviewed. The data suggest that beta-blockers particularly those without intrinsic sympathomimetic activity (ISA) improve long-term survival after myocardial infarction. Platelet-active drugs reduce the rate of reinfarctions and may have a beneficial effect on survival. In contrast lipid-lowering regimens, anticoagulants, calcium channel blockers, and antiarrhythmics have not shown convincing beneficial effects on survival thus far. Difficulties with subgroup analysis and statistical evaluation of treatment effects are discussed.
No takes yet. Share an insight, caveat, or question.
Curt D. Furberg (1988) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: